CancerDrs

Head and Neck Cancer clinical trials

300 actively recruiting head and neck cancer trials in the United States. Cancers of the oral cavity, pharynx, larynx, and salivary glands. HPV-driven and smoking-driven subtypes behave differently; trials often stratify on HPV status.

Data from ClinicalTrials.gov · last refreshed · Head and Neck Cancer stats on SEER

56
Phase 1
110
Phase 2
12
Phase 3
5
Phase 4
117
Other

Head and Neck Cancer by the numbers (U.S.)

59,660
Estimated new cases (2025)
12,770
Estimated deaths (2025)
69.5%
5-year relative survival
65
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse head and neck cancer trials by state

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona

+ 103 more sites in the U.S.

Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Locations:
  • Site 160 — Mobile, Alabama
  • Site 102 — Prescott, Arizona
  • Site 125 — Scottsdale, Arizona

+ 59 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Locations:
  • GSK Investigational Site — Jonesboro, Arkansas
  • GSK Investigational Site — Los Angeles, California
  • GSK Investigational Site — Solvang, California

+ 33 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Locations:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona
  • University of California Los Angeles — Los Angeles, California

+ 25 more sites in the U.S.

Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Locations:
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California

+ 25 more sites in the U.S.

Phase 3 Recruiting Industry

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • City of Hope — Duarte, California
  • University of California at San Diego Moores Cancer Center — La Jolla, California

+ 23 more sites in the U.S.

Phase 2, Phase 3 Recruiting Industry

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unresectable recurrent or metastatic HPV16+ …

Sponsor: BioNTech SE
NCT ID: NCT04534205
Locations:
  • California Research Institute — Los Angeles, California
  • UCLA Cancer Care — Los Angeles, California
  • Stanford Cancer Institute — Palo Alto, California

+ 16 more sites in the U.S.

Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Locations:
  • Helios CR Inc./RadNet — Cerritos, California
  • City of Hope National Cancer Center — Duarte, California
  • Hoag Memorial Hospital — Irvine, California

+ 12 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…

Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Locations:
  • Providence Medical Foundation — Fullerton, California
  • Henry Ford Health System — Detroit, Michigan
  • Baptist Cancer Center — Memphis, Tennessee

+ 3 more sites in the U.S.

Phase 2, Phase 3 Recruiting NIH

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Background: People have 4 parathyroid glands near the thyroid gland in the neck. Surgery is needed to remove a parathyroid gland that is too large or has a tumor. These glands can be in different places, so doctors use an imaging scan with…

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT ID: NCT07444723
Locations:
  • National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 3 Recruiting Academic/Other

Head and Neck Cancer Study Project in the Geriatric Population

This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as …

Sponsor: Brown University
NCT ID: NCT06998069
Locations:
  • Rhode Island and The Miriam Hospitals — Providence, Rhode Island
Phase 3 Recruiting Academic/Other

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…

Sponsor: Mayo Clinic
NCT ID: NCT06915727
Locations:
  • Mayo Clinic in Rochester — Rochester, Minnesota

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27